Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma

Int J Dermatol. 2019 Jul;58(7):e138-e140. doi: 10.1111/ijd.14415. Epub 2019 Feb 27.

Authors

Elisa Cinotti¹, Diletta Fiorani¹, Luca Provvidenziale¹, Clelia Miracco², Vanessa Calamai³, Riccardo Danielli³, Pietro Rubegni¹

Affiliations

¹ Dermatology Unit, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.
² Pathology Unit, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.
³ Medical Oncology and Immunotherapy Unit, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.

PMID: 30810218
DOI: 10.1111/ijd.14415

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Chemotherapy, Adjuvant / adverse effects
Chemotherapy, Adjuvant / methods
Dermoscopy
Humans
Male
Melanoma / pathology
Melanoma / therapy*
Middle Aged
Nivolumab / adverse effects*
Porokeratosis / chemically induced*
Porokeratosis / diagnosis
Porokeratosis / pathology
Skin / diagnostic imaging
Skin / pathology
Skin Neoplasms / pathology
Skin Neoplasms / therapy*

Substances

Antineoplastic Agents, Immunological
Nivolumab